Compare Msci Inc (MSCI) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Stryker Corporation — how do they compare? Msci Inc trades at $563 (market cap $40.84B), while Stryker Corporation trades at $345.72 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 3.3× Msci Inc's market cap, and Msci Inc pays the higher dividend (1.46%). Which is the better fit depends on your goals.
| MSCI | SYK | |
|---|---|---|
Market Cap | $40.84B | $133.54B |
Sector | Financials | Technology |
52-Week High | $643.83 | $394.34 |
52-Week Low | $511.84 | $282.58 |
Enterprise Value | $47.00B | $145.01B |
Dividend Yield | 1.46% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $559.73, down 0.59% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported Q2 2026 earnings of $4.94 per share, slightly missing expectations, but maintains strong fundamentals with a 40.73% net income margin and $3.13 billion in 2025 revenue. Recent developments include the completed acquisition of First Street and a strategic partnership with UBS to enhance private markets transparency.
The stock presents a compelling opportunity with a consensus price target of $728.14, implying significant upside, supported by robust profitability and recurring revenue streams. Key risks include high valuation multiples, such as a P/E of 30.71, and substantial long-term debt of $4.51 billion, which could pressure equity if interest rates rise.
Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.
Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
